Introduction In a monumental stride forward for pulmonary arterial hypertension (PAH) treatment, the FDA's recent approval of the drug Winrevair has sparked a wave of optimism within the medical community. This breakthrough heralds a new era in managing PAH, offering hope to patients grappling with this debilitating condition. Understanding PAH...
